Caroline G Watts1, Anne E Cust1, Scott W Menzies2, Elliot Coates2, Graham J Mann3, Rachael L Morton4. 1. Cancer Epidemiology and Services Research, Sydney School of Public Health, University of Sydney, Sydney, Australia. 2. Sydney Melanoma Diagnostic Centre, Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, Australia3Discipline of Dermatology, Sydney Medical School, University of Sydney, Sydney, Australia. 3. Centre for Cancer Research, Westmead Millennium Institute, University of Sydney, Sydney, Australia5Melanoma Institute Australia, Sydney, Australia. 4. Sydney School of Public Health, University of Sydney, Sydney, Australia7Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, England.
Abstract
IMPORTANCE: Regular surveillance of individuals at high risk for cutaneous melanoma improves early detection and reduces unnecessary excisions; however, a cost analysis of this specialized service has not been undertaken. OBJECTIVE: To determine the mean cost per patient of surveillance in a high-risk clinic from the health service and societal perspectives. DESIGN, SETTING, AND PARTICIPANTS: We used a bottom-up microcosting method to measure resource use in a consecutive sample of 102 patients treated in a high-risk hospital-based clinic in Australia during a 12-month period. EXPOSURE: Surveillance and treatment of melanoma. MAIN OUTCOMES AND MEASURES: All surveillance and treatment procedures were identified through direct observation, review of medical records, and interviews with staff and were valued using scheduled fees from the Australian government. Societal costs included transportation and loss of productivity. RESULTS: The mean number of clinic visits per year was 2.7 (95% CI, 2.5-2.8) for surveillance and 3.8 (95% CI, 3.4-4.1) for patients requiring surgical excisions. The mean annual cost per patient to the health system was A $882 (95% CI, A $783-$982) (US $599 [95% CI, US $532-$665]); the cost discounted across 20 years was A $11,546 (95% CI, A $10,263-$12,829) (US $7839 [95% CI, US $6969-$8710]). The mean annual societal cost per patient (excluding health system costs) was A $972 (95% CI, A $899-$1045) (US $660 [95% CI, US $611-$710]); the cost discounted across 20 years was A $12,721 (95% CI, A $12,554-$14,463) (US $8637 [95% CI, US $8523-$9820]). Diagnosis of melanoma or nonmelanoma skin cancer and frequent excisions for benign lesions in a relatively small number of patients was responsible for positively skewed health system costs. CONCLUSIONS AND RELEVANCE: Microcosting techniques provide an accurate cost estimate for the provision of a specialized service. The high societal cost reflects the time that patients are willing to invest to attend the high-risk clinic. This alternative model of care for a high-risk population has relevance for decision making about health policy.
IMPORTANCE: Regular surveillance of individuals at high risk for cutaneous melanoma improves early detection and reduces unnecessary excisions; however, a cost analysis of this specialized service has not been undertaken. OBJECTIVE: To determine the mean cost per patient of surveillance in a high-risk clinic from the health service and societal perspectives. DESIGN, SETTING, AND PARTICIPANTS: We used a bottom-up microcosting method to measure resource use in a consecutive sample of 102 patients treated in a high-risk hospital-based clinic in Australia during a 12-month period. EXPOSURE: Surveillance and treatment of melanoma. MAIN OUTCOMES AND MEASURES: All surveillance and treatment procedures were identified through direct observation, review of medical records, and interviews with staff and were valued using scheduled fees from the Australian government. Societal costs included transportation and loss of productivity. RESULTS: The mean number of clinic visits per year was 2.7 (95% CI, 2.5-2.8) for surveillance and 3.8 (95% CI, 3.4-4.1) for patients requiring surgical excisions. The mean annual cost per patient to the health system was A $882 (95% CI, A $783-$982) (US $599 [95% CI, US $532-$665]); the cost discounted across 20 years was A $11,546 (95% CI, A $10,263-$12,829) (US $7839 [95% CI, US $6969-$8710]). The mean annual societal cost per patient (excluding health system costs) was A $972 (95% CI, A $899-$1045) (US $660 [95% CI, US $611-$710]); the cost discounted across 20 years was A $12,721 (95% CI, A $12,554-$14,463) (US $8637 [95% CI, US $8523-$9820]). Diagnosis of melanoma or nonmelanoma skin cancer and frequent excisions for benign lesions in a relatively small number of patients was responsible for positively skewed health system costs. CONCLUSIONS AND RELEVANCE: Microcosting techniques provide an accurate cost estimate for the provision of a specialized service. The high societal cost reflects the time that patients are willing to invest to attend the high-risk clinic. This alternative model of care for a high-risk population has relevance for decision making about health policy.
Authors: Wei-Yin Lim; Rachael L Morton; Robin M Turner; Marisa C Jenkins; Pascale Guitera; Les Irwig; Angela C Webster; Mbathio Dieng; Robyn P M Saw; Donald Low; Cynthia Low; Katy J L Bell Journal: JAMA Dermatol Date: 2018-04-01 Impact factor: 10.282
Authors: Deonna M Ackermann; Mbathio Dieng; Ellie Medcalf; Marisa C Jenkins; Cathelijne H van Kemenade; Monika Janda; Robin M Turner; Anne E Cust; Rachael L Morton; Les Irwig; Pascale Guitera; H Peter Soyer; Victoria Mar; Jolyn K Hersch; Donald Low; Cynthia Low; Robyn P M Saw; Richard A Scolyer; Dorothy Drabarek; David Espinoza; Anthony Azzi; Alister M Lilleyman; Amelia K Smit; Peter Murchie; John F Thompson; Katy J L Bell Journal: JAMA Dermatol Date: 2022-01-01 Impact factor: 11.816
Authors: Megan H Trager; Dawn Queen; Faramarz H Samie; Richard D Carvajal; David R Bickers; Larisa J Geskin Journal: Am J Med Date: 2019-11-09 Impact factor: 4.965
Authors: A E Cust; C Badcock; J Smith; N E Thomas; L E Haydu; B K Armstrong; M H Law; J F Thompson; P A Kanetsky; C B Begg; Y Shi; A Kricker; I Orlow; A Sharma; S Yoo; S F Leong; M Berwick; D W Ollila; S Lo Journal: Br J Dermatol Date: 2019-11-27 Impact factor: 9.302
Authors: Deonna M Ackermann; Amelia K Smit; Monika Janda; Cathelijne H van Kemenade; Mbathio Dieng; Rachael L Morton; Robin M Turner; Anne E Cust; Les Irwig; Jolyn K Hersch; Pascale Guitera; H Peter Soyer; Victoria Mar; Robyn P M Saw; Donald Low; Cynthia Low; Dorothy Drabarek; David Espinoza; Jon Emery; Peter Murchie; John F Thompson; Richard A Scolyer; Anthony Azzi; Alister Lilleyman; Katy J L Bell Journal: Trials Date: 2021-05-04 Impact factor: 2.279
Authors: Clare Amy Primiero; Aideen M McInerney-Leo; Brigid Betz-Stablein; David C Whiteman; Louisa Gordon; Liam Caffery; Joanne F Aitken; Elizabeth Eakin; Sonya Osborne; Len Gray; B Mark Smithers; Monika Janda; H Peter Soyer; Anna Finnane Journal: BMJ Open Date: 2019-11-10 Impact factor: 2.692